The global sleeping pills market is set to reach US$9 billion by the year 2015. Though the present market is tormented with safety concerns on one side and entry of generics following patent expiry of leading prescription pill, Ambien, on the other side, significant unmet medical needs exist, which bodes considerable opportunities for novel pills to make a mark in the sleeping pills market. Development of drugs with lower side effects and perils of overdose would be the mainstay focus of drug manufacturers in the future. Non-benzodiazepines such as Ambien, Sonata, and Lunesta are the most prescribed pills, and will remain the most preferred in near future.
More than 55% of the US population is affected from symptoms of Insomnia, and close to 15% suffer from serious insomnia. Insomnia has become a major health issue the world over, and as a result, more and more people are seeking medical intervention for relief. The use of sleeping pills as a sleeping aid has become increasingly common, with about 10-20% of the global population currently using sleeping pills or tranquilizers to relieve Insomnia and other sleep disorders. Further, in contrast to the past, the use of sleeping pills is no longer confined to only the elderly. Sleep disorders are affecting individuals across all age groups, as indicated by the two-fold rise in number of people belonging to the 20-45 age group having used sleeping pills during the period 2000-2004.
A primary concern of sleeping pills is associated with their side effects of drowsiness the next day, drug dependency, and drug tolerance. As a result, unmet medical needs continue to exist in the market, as it awaits novel drugs with improved safety and efficacy profiles. These factors bode substantial opportunities for novel drugs with lower side effects. Besides safety concerns, the sleeping pills market is presently characterized by a weak pipeline, entry of generics after the patent expiry of Sanofi-Aventis' Ambien (Zolpidem).
The US represents the largest market for sleeping pills globally, accounting for a share of more than 48%. The market for sleeping pills in the US has witnessed a steady growth, with the total number of prescriptions having reached 57.25 million in 2008. Europe has about 32,746 million people affected by Insomnia. Within Europe, France has the highest prevalence rate of people affected from sleeping disorders, with people in the age group of 50-59 being the most highly affected.
In terms of brands, the sleeping pills market is expected to witness several changes in the coming years. Non-benzodiazepines such as Ambien, Sonata, and Lunesta are the most prescribed pills, and are expected to remain the most preferred in near future, as stated by a new market research report on Sleeping Pills. The popularity of these brands is attributed to their lower risk of dependence, when compared to Benzodiazepines. However, the market share structure in terms of volume is expected to see some major changes. Patent expiry of Sanofi-Aventis' leading sleeping pill- Ambien - in 2007 led to the entry of generic versions for this drug, altering the market landscape of sleeping pills. The market has also seen the emergence of a new class of drugs, Melatonin Receptor Agonist Hypnotics, which acts on Melatonin receptors in the brain. Rozerem is one such drug, which is claimed to be devoid of the risk of drug dependency.
The report titled Sleeping Pills: A Global Strategic Business Report provides a strategic review of the sleeping pills market, major brands available worldwide, current market trends, growth drivers, patent expiry of Ambien and other noteworthy brands, safety concerns related to the side effects of sleeping pills, pipeline analysis, FDA approvals, critical insights on product classes (Benzodiazipines, non-benzodiazipines, melatonin receptor agonist hypnotic), glimpse into the OTC market, and profiles of prescription as well as generic players. The report analyzes market data and analytics in terms of value sales for geographic markets - United States and Rest of the World.
Major players profiled in the report include Sanofi-Aventis, Sepracor, King Pharmaceuticals, H. Lundbeck A/S, Takeda Pharmaceutical Company, Actelion Pharmaceuticals, Apotex Inc., Abbott Laboratories, Neurocrine Biosciences, Transcept Pharmaceuticals Inc., Aurobindo Pharma Ltd., Caraco Pharmaceutical Laboratories Ltd., Dr. Reddy's Laboratories Limited, Ranbaxy Laboratories Ltd., Roxane Laboratories Inc., Sandoz International GmbH, Somaxon Pharmaceuticals Inc., Synthon BV, among others.
Click for report details: Sleeping Pills - A Global Strategic Business Report